Candriam SCA’s ResMed RMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.46M | Buy |
10,945
+425
| +4% | +$106K | 0.01% | 481 |
|
|
2025
Q4 | $2.53M | Hold |
10,520
| – | – | 0.01% | 474 |
|
|
2025
Q3 | $2.88M | Buy |
10,520
+721
| +7% | +$197K | 0.02% | 444 |
|
|
2025
Q2 | $2.53M | Sell |
9,799
-296
| -3% | -$70.6K | 0.01% | 466 |
|
|
2025
Q1 | $2.26M | Sell |
10,095
-638
| -6% | -$149K | 0.01% | 473 |
|
|
2024
Q4 | $2.45M | Buy |
10,733
+630
| +6% | +$152K | 0.01% | 468 |
|
|
2024
Q3 | $2.47M | Buy |
10,103
+732
| +8% | +$164K | 0.01% | 475 |
|
|
2024
Q2 | $1.79M | Buy |
9,371
+912
| +11% | +$185K | 0.01% | 507 |
|
|
2024
Q1 | $1.68M | Buy |
8,459
+1,089
| +15% | +$200K | 0.01% | 536 |
|
|
2023
Q4 | $1.27M | Hold |
7,370
| – | – | 0.01% | 557 |
|
|
2023
Q3 | $1.09M | Sell |
7,370
-33,733
| -82% | -$6.1M | 0.01% | 539 |
|
|
2023
Q2 | $8.98M | Sell |
41,103
-14,425
| -26% | -$3.22M | 0.06% | 258 |
|
|
2023
Q1 | $11.2M | Buy |
55,528
+3,053
| +6% | +$662K | 0.08% | 244 |
|
|
2022
Q4 | $10.9M | Sell |
52,475
-2,872
| -5% | -$631K | 0.07% | 258 |
|
|
2022
Q3 | $12.1M | Buy |
55,347
+19,349
| +54% | +$4.4M | 0.09% | 230 |
|
|
2022
Q2 | $7.55M | Sell |
35,998
-6,897
| -16% | -$1.47M | 0.06% | 268 |
|
|
2022
Q1 | $10.4M | Sell |
42,895
-20,337
| -32% | -$4.92M | 0.07% | 251 |
|
|
2021
Q4 | $16.5M | Buy |
63,232
+45,056
| +248% | +$11.7M | 0.11% | 198 |
|
|
2021
Q3 | $4.79M | Sell |
18,176
-731
| -4% | -$200K | 0.03% | 408 |
|
|
2021
Q2 | $4.66M | Buy |
18,907
+1,132
| +6% | +$238K | 0.03% | 419 |
|
|
2021
Q1 | $3.63M | Hold |
17,775
| – | – | 0.03% | 426 |
|
|
2020
Q4 | $3.78M | Buy |
17,775
+1,400
| +9% | +$279K | 0.03% | 437 |
|
|
2020
Q3 | $2.81M | Sell |
16,375
-30,510
| -65% | -$5.63M | 0.03% | 449 |
|
|
2020
Q2 | $9M | Buy |
46,885
+35,351
| +306% | +$5.78M | 0.1% | 230 |
|
|
2020
Q1 | $1.75M | Hold |
11,534
| – | – | 0.02% | 555 |
|
|
2019
Q4 | $1.79M | Buy |
11,534
+2,434
| +27% | +$351K | 0.02% | 572 |
|
|
2019
Q3 | $1.23M | Sell |
9,100
-401
| -4% | -$52.5K | 0.02% | 571 |
|
|
2019
Q2 | $1.15M | Buy |
+9,501
| New | +$1.05M | 0.01% | 625 |
|
|
2019
Q1 | – | Sell |
-36,570
| Closed | -$4.16M | – | 828 |
|
|
2018
Q4 | $4.16M | Buy |
36,570
+28,504
| +353% | +$3.05M | 0.06% | 317 |
|
|
2018
Q3 | $930K | Buy |
+8,066
| New | +$884K | 0.01% | 634 |
|
Other funds holding RMD
VCM
VPM
DAM
Candriam SCA's RMD Position: Q1 2026 in Review
Candriam SCA increased its ResMed (RMD) stake by 4% in Q1 2026, buying an estimated $106K and bringing the position to 10,945 shares worth $2.46M. The position accounts for 0.01% of the portfolio, ranked #481.
Candriam SCA first reported a position in RMD in Q3 2018 and has held it in 30 quarters since. The position peaked at $16.5M in Q4 2021. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.
- Candriam SCA held 10,945 shares of ResMed worth $2.46M as of Q1 2026.
- Candriam SCA bought 425 ResMed shares in Q1 2026, an estimated $106K.
- ResMed made up 0.01% of Candriam SCA's portfolio in Q1 2026, its #481 holding.
- Candriam SCA first reported a position in ResMed in Q3 2018 and has held it in 30 quarters since.
- Candriam SCA's ResMed position peaked at $16.5M in Q4 2021.
- 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.
Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.